Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2022
Covalent inhibitors of EZH2: Design, synthesis and evaluationQiangsheng Zhang, Xinyi Chen, Xi Hu, et al.European Journal of Medicinal Chemistry|June 22, 2024
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitorZuli Hu, Qiangsheng Zhang, Zulong Li, et al.Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|July 8, 2025
Metal ion-induced structural reconstruction in a porphyrin MOF for ultrasensitive detection of Cr3+ and Al3Tianhong Liu, Mengyu Yin, Wenhao Du, et al.European Journal of Medicinal Chemistry|July 12, 2023
Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutantsYingyue Yang, Xiaojie He, Zulong Li, et al.Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|April 10, 2024
Multifunctional fluorescent probe for simultaneous revealing Cys and ONOO- dynamic correlation in the ferroptosisXiongbo Liu, Jiali Zhu, Qiangsheng Zhang, et al.Journal of Medicinal Chemistry|January 24, 2023
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian CancerQiangsheng Zhang, Xinyi Chen, Jiaying Cao, et al.Journal of Medicinal Chemistry|November 30, 2022
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of CancerGuoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, et al.Journal of Medicinal Chemistry|February 19, 2021
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Zhihao Liu, Xi Hu, Qiwei Wang, et al.Pageof 4